Events

Alere NT-proBNP for ARCHITECT Controls 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Abbott Laboratories 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2018-09-04
  • 사례 출판 날짜
    2018-09-04
  • 사례 국가
    Hong Kong
  • 사례 출처
    DH
  • 사례 출처 URL
    https://www.mdco.gov.hk/english/safety/recalls/recalls_20180904b.html
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: abbott alere nt-probnp for architect controls medical device manufacturer, abbott laboratories, has issued a medical device safety alert concerning its alere nt-probnp for architect controls. the affected devices are identified as follow: list number: 2r10-10; lot number: a) 902917627; b) 902918346 expiration date: a) 19 december 2018; b) 16 february 2019 udi number: a) (01)05055845400404(17)181219(10)902917627; b) (01)05055845400404(17)190216(10)902918346 abbot laboratories becomes aware that the manufacturer of the alere nt-probnp for architect controls, axis-shield, has identified a stability issue that may lead to quality control values falling outside of expected ranges prior to assigned expiry date. according to the manufacturer, a potential delay may exist in the reporting of patient results due to quality control values falling outside of expected ranges. internal testing on patient samples showed no atypical bias for the impacted lots, therefore if quality controls are in range, patient results are not impacted. if affected users have an alternate control lot available in inventory, they should immediately discontinue use of the affected control lot(s) and switch to the alternate control lot. they should also destroy any remaining inventory of impacted material according to their laboratory procedures. if the affected users do not have an alternate control lot available in inventory and the current lot continues to generate valid qc results, they should immediately order a replacement control lot. they may continue to use the affected control lot(s) while following their current laboratory qc procedures. once they receive the replacement control lot, they may destroy any remaining inventory of impacted material according to their laboratory procedures. product replacement is on-going. according to the local supplier, the affected products are distributed in hong kong. if you are in possession of the products, please contact your supplier for necessary actions. posted on 4 september 2018.

Device

Alere NT-proBNP for ARCHITECT Controls
  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Abbott Alere NT-proBNP for ARCHITECT Controls
  • Manufacturer
    Abbott Laboratories

Manufacturer

Abbott Laboratories
  • 제조사 모회사 (2017)
    Abbott Laboratories
  • 제조사 의견
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    DH